Spinal Muscular Atrophy Type 3Symptoms, Doctors, Treatments, Advances & More
Spinal Muscular Atrophy Type 3 Overview
Learn About Spinal Muscular Atrophy Type 3
UCLA Health Westwood Neurology
Perry Shieh is a Neurologist practicing medicine in Los Angeles, California. Dr. Shieh is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. He is also highly rated in 47 other conditions, according to our data. His clinical expertise encompasses Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Tubular Aggregate Myopathy.
Clinical Research Center
Jeffrey Statland is a Neurologist practicing medicine in Fairway, Kansas. Dr. Statland is rated as an Elite provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. He is also highly rated in 51 other conditions, according to our data. His clinical expertise encompasses Facioscapulohumeral Muscular Dystrophy (FSHD), Paramyotonia Congenita, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, and Gastrostomy. Dr. Statland is board certified in American Board Of Psychiatry And Neurology, Neurology - 2011. Dr. Statland is currently accepting new patients.
Swedish Neurology - Cherry Hill
Michael Elliott is a Neuromusculoskeletal Medicine specialist and a Neurologist practicing medicine in Seattle, Washington. Dr. Elliott is rated as a Distinguished provider by MediFind in the treatment of Spinal Muscular Atrophy Type 3. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Spinal Muscular Atrophy (SMA), Spinal and Bulbar Muscular Atrophy, and Spinal Muscular Atrophy Type 3. Dr. Elliott is board certified in American Board Of Psychiatry And Neurology and American Board Of Electrodiagnostic Medicine. Dr. Elliott is currently accepting new patients.
Summary: This is a phase I/II clinical study to evaluate the safety, preliminary efficacy and immunogenicity of SKG0201 injection in subjects with Spinal Muscular Atrophy Type I.
Summary: GB221 is a gene therapy that delivers a working SMN1 gene to the motor neurons of people with spinal muscular atrophy (SMA) Type 1. This study will evaluate the safety, tolerability and efficacy of GB221 in two groups: 1. participants aged from 2 weeks to younger than 12 months presenting with symptoms of SMA Type 1 who have never received a treatment OR are receiving the drug risdiplam 2. partici...

